



Universiteit  
Leiden  
The Netherlands

## Targeting inter-organ cross-talk in cardiometabolic diseases

Liu, C.

### Citation

Liu, C. (2023, May 16). *Targeting inter-organ cross-talk in cardiometabolic diseases*. Retrieved from <https://hdl.handle.net/1887/3618361>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3618361>

**Note:** To cite this publication please use the final published version (if applicable).

# 5

## FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis

Cong Liu<sup>1,2</sup>, Milena Schönke<sup>1,2</sup>, Borah Spoorenberg<sup>1,2</sup>, Joost M. Lambooi<sup>3,4</sup>, Hendrik J.P. van der Zande<sup>3</sup>, Enchen Zhou<sup>1,2</sup>, Maarten E. Tushuizen<sup>5</sup>, Anne-Christine Andréasson<sup>6</sup>, Andrew Park<sup>7</sup>, Stephanie Oldham<sup>8</sup>, Martin Uhrbom<sup>6</sup>, Ingela Ahlstedt<sup>6</sup>, Yasuhiro Ikeda<sup>7</sup>, Kristina Wallenius<sup>6</sup>, Xiao-Rong Peng<sup>6</sup>, Bruno Guigas<sup>3</sup>, Mariëtte R. Boon<sup>1,2</sup>, Yanan Wang<sup>1,2,9</sup>, Patrick C.N. Rensen<sup>1,2,9</sup>

<sup>1</sup> Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.

<sup>2</sup> Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.

<sup>3</sup> Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.

<sup>4</sup> Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.

<sup>5</sup> Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.

<sup>6</sup> Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.


<sup>7</sup> Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, USA.

<sup>8</sup> Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.

<sup>9</sup> Med-X institute, Center for Immunological and Metabolic Diseases, and Department of Endocrinology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Xi'an, China.

**eLife, 2023; 12: e83075.**

## ABSTRACT



Analogues of the hepatokine FGF21 are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and insulin-sensitizing effects have been largely unraveled, the mechanisms by which they alleviate liver injury have only been scarcely addressed. Here, we aimed to unveil the mechanisms underlying the protective effects of FGF21 on NASH using APOE\*3-Leiden.CETP mice, a well-established model for human-like metabolic diseases. Liver-specific FGF21 overexpression was achieved in mice, followed by administration of a high-fat high-cholesterol diet for 23 weeks. FGF21 prevented hepatic lipotoxicity, accompanied by activation of thermogenic tissues and attenuation of adipose tissue inflammation, improvement of hyperglycemia and hypertriglyceridemia, and upregulation of hepatic programs involved in fatty acid oxidation and cholesterol removal. Furthermore, FGF21 inhibited hepatic inflammation, as evidenced by reduced Kupffer cell (KC) activation, diminished monocyte infiltration and lowered accumulation of monocyte-derived macrophages. Moreover, FGF21 decreased lipid- and scar-associated macrophages, which correlated with less hepatic fibrosis as demonstrated by reduced collagen accumulation. Collectively, hepatic FGF21 overexpression limits hepatic lipotoxicity, inflammation and fibrogenesis. Mechanistically, FGF21 blocks hepatic lipid influx and accumulation through combined endocrine and autocrine signaling, respectively, which prevents KC activation and lowers the presence of lipid- and scar-associated macrophages to inhibit fibrogenesis.

## INTRODUCTION

The liver is the nexus of many metabolic pathways, including those of glucose, fatty acids (FAs) and cholesterol. In health, these metabolites are distributed to peripheral tissues while preventing long-lasting accumulation in the liver. In a pathological state, however, lipids may accrue in the liver, thereby impairing liver function and carving the path towards the development of nonalcoholic fatty liver disease (NAFLD) [1]. NAFLD is considered a spectrum of liver diseases ranging from liver steatosis, characterized by lipid accumulation in hepatocytes, to nonalcoholic steatohepatitis (NASH) with hepatic steatosis, lobular inflammation, hepatocyte ballooning and varying degrees of fibrosis [2, 3]. Patients diagnosed with NASH are predisposed to developing cirrhosis and hepatocellular carcinoma, among whom patients with severe liver fibrosis are at greatest risk of overall- and liver-related mortality [4]. Despite this, there are currently no approved pharmaceutical therapeutics for NASH. Instead, lifestyle modifications remain the first-line treatment for NASH, although this is rarely attainable in the long term, and liver transplantation is still the sole intervention to treat the end-stage of NASH [2, 5]. Thus, there is an unmet need for therapeutic strategies that control the progression of NASH, in particular of liver fibrosis, and reverse the underlying pathophysiology.

Current hypotheses suggest that adipose tissue dysfunction and lipid spillover leads to hepatic lipotoxicity, and thereby the initiation of NASH [6, 7], which further progresses through the inflammatory response triggered by hepatic lipotoxicity [7]. This inflammatory response and subsequent fibrogenesis are primarily initiated by liver macrophages [8]. Hepatic macrophages mainly consist of embryonically-derived macrophages, termed resident Kupffer cells (ResKCs), and monocyte-derived macrophages (MoDMacs) that are recruited from the circulation [9]. In the steady state, ResKCs serve as sentinels for liver homeostasis. In NASH, liver injury caused by excess lipids and hepatocyte damage/death, triggers ResKC activation, leading to pro-inflammatory cytokine and chemokine release [10]. This fosters the infiltration of newly-recruited monocytes into the liver, which gives rise to various pro-inflammatory and pro-fibrotic macrophage subsets [8, 10]. Interestingly, recent preclinical and clinical studies have reported that modulation of ResKC activation, monocyte recruitment or macrophage differentiation, to some extent, can attenuate NASH [8, 11]. In light of these findings, FGF21, a hepatokine with both lipid-lowering and anti-inflammatory properties [12, 13], has been brought to the foreground as a promising potential therapeutic to treat NASH.


The specificity of FGF21 action for various metabolic tissues is determined by the FGF receptor (FGFR) which forms a heterodimer with the transmembrane co-receptor  $\beta$ -Klotho (KLB) [14, 15]. While the FGFR is ubiquitously expressed, KLB is primarily expressed in the liver and adipose tissue [14, 15], therefore possibly limiting FGF21 action to these tissues. Physiologically, FGF21 is considered a stress-induced hormone whose levels rise in metabolically compromised states, such as obesity [16] and NASH [17]. The increased FGF21 in these pathologies is likely induced by an accumulation of lipids in the liver [18]. As such, plasma FGF21 also positively correlates with the severity of steatohepatitis and fibrosis in patients with NASH [17]. Induction of FGF21 is thought to mediate a compensatory response to limit metabolic dysregulation [19], although this level is not sufficient. Interestingly, two phase 2a clinical trials reported that pharmacological FGF21 treatment improves liver steatosis in NASH patients [20, 21]. While an *in vivo* study testing the therapeutic potency of FGF21 in choline-deficient and high-fat diet-induced NASH has previously reported both anti-inflammatory and anti-fibrotic effects [22], detailed mechanistic understanding is still lacking.

In the present study, we aimed to elucidate the mechanisms underlying FGF21-mediated improvement of NASH, in particular of steatohepatitis and fibrogenesis. To this end, we used *APOE\*3-Leiden.CETP* mice, a well-established model for human cardiometabolic diseases. These mice exhibit human-like lipoprotein metabolism, develop hyperlipidemia, obesity and inflammation when fed a high-fat high-cholesterol diet (HFCD), and develop fibrotic NASH closely resembling clinical features that accompany NASH in humans [23, 24]. Moreover, these mice show human-like responses to both lipid-lowering and anti-inflammatory therapeutics during the development of metabolic syndrome [25-28]. Here, we show that specific overexpression of FGF21 in the liver, resulting in increases circulating FGF21 levels, activates hepatic signaling associated with FA oxidation and cholesterol removal. In parallel, FGF21 activates thermogenic tissues and reduces adipose tissue inflammation, thereby protecting against adipose tissue dysfunction, hyperglycemia and hypertriglyceridemia. As a consequence, FGF21 largely limits lipid accumulation in the liver and potently blocks hepatic KC activation and monocyte recruitment, thereby preventing the accumulation of pro-inflammatory macrophages in the liver. In addition, FGF21 reduced the number of pro-fibrotic macrophages in the injured liver, potentially explaining why FGF21 counteracts all features of NASH, including hepatic steatosis, inflammation and fibrogenesis.

## RESULTS

### Liver-specific FGF21 overexpression increases circulating FGF21 levels and protects against HFCD-induced body fat mass gain


We aimed to elucidate the underlying mechanisms of FGF21-mediated hepatoprotective effects on NASH, by using *APOE\*3-Leiden.CETP* mice fed with a HFCD, a model that induces all stages of NASH in a human-like fashion and recapitulates the ultrastructural changes observed in NASH patients [23, 24]. Since the liver is the main contributor to circulating FGF21 [14], we employed an adeno-associated virus vector 8 (AAV8) vector expressing codon-optimized murine *Fgf21* to induce liver-specific FGF21 overexpression in *APOE\*3-Leiden.CETP* mice. Mice treated with either AAV8-*Fgf21* or AAV8-null as controls were fed with a HFCD for 23 weeks (**Fig. 1A**). We confirmed liver-specific FGF21 overexpression by a large increase in codon-optimized *Fgf21* expression in the liver but not in adipose tissue (**Fig. 1B**), resulting in high circulating FGF21 levels that persisted throughout the study (**Fig. 1C**). In addition, we observed that HFCD feeding increased hepatic endogenous *Fgf21* expression (+184%), which, however, was prevented by AAV8-*Fgf21* administration (**Fig. 1B**). Furthermore, by performing a student *t*-test between the LFCD and HFCD groups, we did observe that as compared to the LFCD group, HFCD feeding increased plasma FGF21 levels at week 4 (+52%) and week 23 (+383%) (**Fig. 1C**). These results are in agreement with previous findings showing that FGF21 is a stress-induced hepatokine whose levels increase in metabolically compromised states, such as obesity [16] and NAFLD [17]. HFCD progressively and profoundly increased body weight over the experimental period, accompanied by increased white adipose tissue (WAT) and brown adipose tissue (BAT) weights relative to those of low fat low cholesterol (LFCD)-fed mice (**Fig. 1D,E**). In favorable contrast, FGF21 reduced body weight in the first 3 weeks, after which body weight stabilized and remained lower than that of LFCD- and HFCD-fed mice by the end of the study (-18% and -35%, respectively; **Fig. 1D**). Concomitantly, FGF21 decreased weights of gonadal WAT (gWAT; -67%), subcutaneous WAT (sWAT; -55%), interscapular BAT (iBAT; -41%) and subscapular BAT (-41%) to levels comparable to those observed in LFCD-fed mice (**Fig. 1E**). These findings thus highlight the potent effects of FGF21 on preventing fat mass gain under NASH-inducing dietary conditions.



**Fig. 1. Liver-specific FGF21 overexpression increases circulating FGF21 levels and protects against HFCD-induced body fat mass gain.** (A) Experimental set up. (B) At week 23, codon-optimized FGF21 mRNA expression in the liver and gWAT was quantified (n=16-18), and endogenous *Fgf21* expression in the liver was also measured (n=16-18). (C) Plasma FGF21 levels were measured before (at week -1; pooled samples, n=6 per group) and after (at week 4, pooled samples, n=6 per group; week 23, n=12-16 per group) AAV8-*Fgf21* administration. (D) Body weight was monitored throughout the experimental period (n=17-18). (E) At week 23, brown adipose tissue (BAT) and white adipose tissue (WAT) depots were isolated and weighed (n=18). Data are shown as mean±SEM. Differences were assessed using one-way ANOVA followed by a Tukey post-test. \* $P < 0.05$ ; \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , compared with the LFCD group. ### $P < 0.001$ , compared with the HFCD group. (C) Differences between the LFCD and HFCD groups were assessed using student t test.  $^{ss}P < 0.01$ , compared the LFCD group. AAV8, adeno-associated virus 8; FGF21, fibroblast growth factor 21; gWAT, gonadal WAT; HFCD, high fat and high cholesterol diet; iBAT, interscapular BAT; LFCD, low fat and low cholesterol diet; sBAT, subscapular BAT; sWAT, subcutaneous white adipose tissue.

## FGF21 protects against HFCD-induced adipose tissue dysfunction

The profound fat mass-lowering effects of liver-derived FGF21 prompted us to examine its role in adipose tissue function. Since we and others have previously shown that FGF21 activates thermogenic adipose tissues [29, 30], we first performed histological analyses of BAT and sWAT, the adipose tissue that is most prone to browning [31]. We observed that FGF21 prevented the HFCD-induced lipid overload in BAT (-66%) and increased uncoupling protein-1 (UCP-1) expression compared with both the LFCD- and HFCD-fed groups (+15% and +26%, respectively) (Fig. 2A). In sWAT, FGF21 prevented HFCD-induced adipocyte hypertrophy (-41%), and increased the UCP-1 content (+94%) (Fig. 2B). Among the adipose tissue depots, gWAT is most prone to diet-induced inflammation, and surgical removal of inflamed gWAT attenuates NASH in obese mice [32]. Similar to sWAT, FGF21 protected against HFCD-induced adipocyte enlargement (-52%) in gWAT and in addition fully prevented the formation of crown-like structures (CLSs; -93%) (Fig. 2C). In agreement with these findings, FGF21 suppressed the HFCD-induced expression of adhesion G protein-coupled receptor E1 (*Adgre1*; -56%), encoding the macrophage surface marker F4/80, in addition to decreased expression of the pro-




**Fig. 2. FGF21 protects against HFCD-induced adipose tissue dysfunction.** (A) In iBAT, the lipid content and expression of uncoupling protein-1 (UCP-1) were quantified after H&E staining and UCP-1 immunostaining, respectively. (B) In sWAT, the adipocyte enlargement was assessed by H&E staining, and the tissue browning was evaluated by UCP-1 immunostaining. (C) In gWAT, the adipocyte hypertrophy was detected, and the number of CLSs was assessed, and (D) mRNA expression of pro-inflammatory markers was quantified. (E) Plasma adiponectin concentration in fasted blood plasma was measured at week 22. (A)-(D), n=14-18 per group; (E), n=10 per group. Differences were assessed using one-way ANOVA followed by a Tukey post-test. \* $P < 0.05$ , \*\*\* $P < 0.001$ , compared with the LFCD group. # $P < 0.05$ , ## $P < 0.01$ , ### $P < 0.001$ , compared with the HFCD group. *Adgre1*, adhesion G protein-coupled receptor E1; *Tnfa*, tumor necrosis factor  $\alpha$ ; *Il1b*, interleukin-1 $\beta$ ; *Ccl2*, chemokine C-C motif ligand 2.



inflammatory mediators tumor necrosis factor  $\alpha$  (*Tnfa*; -60%), interleukin-1 $\beta$  (*Il1b*; -50%) and monocyte attractant chemokine C-C motif ligand 2 (*Ccl2*; -60%) (**Fig. 2D**). Besides, FGF21 tended to upregulate *Klb* (+33%) and *Fgfr1* (+30%) expression compared to HFCD-fed mice (**Fig. 2-fg. supplement 1**). Moreover, consistent with the critical role of adiponectin in mediating the therapeutic benefits of FGF21 in adipose tissue[22, 33], FGF21 increased plasma adiponectin levels compared to both LFCD- and HFCD-fed mice (+93% and +133%, respectively; **Fig. 2E**). These combined findings thus indicate that FGF21 prevents HFCD-induced adipose tissue dysfunction during NASH development.

### FGF21 alleviates HFCD-induced hyperglycemia and hypertriglyceridemia

We next examined whether FGF21 confers its glucose and lipid lowering effects during NASH development. While HFCD induced hyperglycemia as compared to LFCD, FGF21 normalized fasting plasma glucose compared to LFCD, which was accompanied by lower glucose excursion after an intraperitoneal glucose tolerance test (**Fig. 3A,B**). In addition, FGF21 normalized the plasma insulin and Homeostatic Model Assessment for Insulin Resistance index (**Fig. 3C**), indicating that FGF21 restores insulin sensitivity to



**Fig. 3. FGF21 alleviates HFCD-induced hyperglycemia and hypertriglyceridemia.** (A) Fasting plasma glucose levels were measured during the experimental period. (B) At week 16, an intraperitoneal glucose tolerance test (IPGTT) was initiated. (B) The area under the curve (AUC) of plasma glucose during the IPGTT and (C) plasma insulin concentration in response to the IPGTT was determined at the indicated timepoints. (C) Homeostasis model assessment of insulin resistance (HOMA-IR) was determined from fasting glucose and insulin levels. (D) Fasting plasma TG levels were measured throughout the study. The distribution of triglyceride over lipoproteins was determined (pooled samples; n=5 per group) from plasma of week 22. (E) At week 20, an oral lipid tolerance test (OLTT) was initiated, and AUC of plasma TG during the OLTT was calculated. (A and D), n=14-18 per group; (B-C), n=7-8 per group; (E), n=6-9 per group. Data are shown as mean $\pm$ SEM. Differences were assessed using one-way ANOVA followed by a Tukey post-test. \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001, compared with the LFCD group. # $P$ <0.05, ## $P$ <0.01, ### $P$ <0.001, compared with the HFCD group.


that observed in LFCD-fed mice. FGF21 did not prevent the HFCD-induced increase of plasma total cholesterol (TC) levels (**Fig. 3-fig. supplement 1A**), nor the distribution of cholesterol over the various lipoproteins (**Fig. 3-fig. supplement 1B**). Nonetheless, FGF21 strongly and consistently reduced fasting plasma triglyceride (TG) levels throughout the experimental period compared with LFCD- and HFCD-fed mice (-67% and -58%; at week 22), which was specific for very-low density lipoprotein (VLDL) and low density lipoprotein (LDL) (**Fig. 3D**). In addition, an oral lipid tolerance test revealed that FGF21 prevented HFCD-induced lipid intolerance (**Fig. 3E**). Taken together, FGF21 prevents the HFCD-induced increase in circulating glucose and reduces circulating TG levels beyond those observed in LFCD-fed mice.

### **FGF21 protects against HFCD-induced hepatic steatosis, inflammation, and fibrogenesis**

Then, we investigated the effects of FGF21 on liver steatosis, inflammation and fibrosis. FGF21 not only prevented HFCD-induced liver weight gain (-58%), but even reduced liver weight to a level lower than that of LFCD-fed mice (-40%; **Fig. 4A,F**). Moreover, FGF21 abolished the HFCD-induced increase in steatosis, lobular inflammation and hepatocellular ballooning (**Fig. 4B, Fig. 4-fig. supplement 1A,B**). Therefore, FGF21 completely prevented the HFCD-induced large increase in the NAFLD activity score (-74%; **Fig. 4C,F**). Furthermore, FGF21 prevented collagen accumulation in the liver as assessed by Picrosirius Red staining (-58%; **Fig. 4D,F**). We then measured hepatic concentration of hydroxyproline, a major constituent of collagen and thus a marker of extracellular matrix accumulation. In line with the hepatic collagen content, HFCD feeding increased the hepatic hydroxyproline content, which was prevented by FGF21 (-49%; **Fig. 4E**). Taken together, our data demonstrate that FGF21 protects against HFCD-induced hepatosteatosis, steatohepatitis as well as fibrogenesis.


### **FGF21 abolishes liver lipotoxicity, accompanied by activation of hepatic signaling involved in FA oxidation and cholesterol removal**

In the context of NASH, pro-inflammatory responses and fibrogenesis occur when hepatocytes are injured by lipotoxicity [7, 34]. Indeed, 23 weeks of HFCD feeding promoted aberrant accumulation of TG as well as TC in the liver (**Fig. 5A**). In agreement with the data presented in **Fig. 4**, FGF21 abrogated the HFCD-induced increase in hepatic TG levels (-62%) and tended to decrease hepatic TC levels (-22%), resulting in smaller lipid droplets (**Fig. 5A**). In addition to reduced lipid overflow from WAT, we reasoned that FGF21 may also directly act on the liver to prevent HFCD-induced liver lipotoxicity. In agreement, compared to both LFCD- and HFCD-fed mice, FGF21 profoundly upregulated the expression of *Klb* (+150% and +223%), *Fgfr1* (+57% and +79%), *Fgfr2* (+97% and +77%), and *Fgfr4* (+53% and +67%) (**Fig. 5-fig. supplement 1**). We next



**Fig. 4. FGF21 protects against HFCD-induced hepatic steatosis, inflammation and fibrosis.** (A) At week 23, liver weight was determined, and (B) scoring of histological features of steatosis, lobular inflammation and ballooning as well as (C) NAFLD activity was evaluated by H&E staining. (D) Liver fibrosis was assessed by Picrosirius Red (PSR) staining, and (E) hepatic hydroxyproline levels were determined. (F) Representative macroscopic, H&E and PSR pictures are shown. Data are shown as mean±SEM (n=16-18 per group). Differences were assessed using one-way ANOVA followed by a Tukey post-test. \* $P<0.05$ ; \*\* $P<0.01$ , \*\*\* $P<0.001$ , compared with the LFCD group. \*\* $P<0.01$ ; \*\*\* $P<0.001$ , compared with the HFCD group

quantified the hepatic expression of key genes involved in FA and cholesterol handling. FGF21 did not attenuate the HFCD-induced increased expression of FA translocase cluster of differentiation 36 (*Cd36*) (Fig. 5-supplement 2A). In favorable contrast, compared to both LFCD- and HFCD-fed mice, FGF21 did increase the expression of carnitine palmitoyl transferase 1 $\alpha$  (*Cpt1a*, +66% and +53%), peroxisome proliferator-activated receptor  $\alpha$  (*Ppara*, +67% and +53%) and peroxisome proliferator-activated receptor  $\gamma$  coactivator 1 $\alpha$  (*Pgc1a*; +188% and +225%), all of those genes being key players involved in FA oxidation (Fig. 5B). Moreover, compared to LFCD- and HFCD-fed mice, FGF21 increased the expression of apolipoprotein B (*Apob*, +26% and +38%), which is involved in VLDL secretion (Fig. 5-fig. supplement 2B). Furthermore, FGF21 upregulated the expression of ATP-binding cassette transporter G member 5 (*Abcg5*; 7-fold and 2-fold), crucial for biliary secretion of neutral sterols (Fig. 5C), increased the



**Fig. 5. FGF21 abolishes liver lipotoxicity, accompanied by activation of hepatic signaling involved in FA oxidation and cholesterol removal.** (A) Triglyceride (TG), total cholesterol (TC) and phospholipid (PL) levels were determined in the liver (n=18 per group), and representative Oil Red O (ORO) pictures are shown. (B) The relative mRNA expression of genes involved in fatty acid oxidation and (C and D) cholesterol removal (n=15-18 per group) were determined in the liver. Data are shown as mean ± SEM. Differences were assessed using one-way ANOVA followed by a Tukey post-test. \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , compared with the LFCD group. \*\*\* $P < 0.001$ , compared with the HFCD group. *Abcg5*, ATP-binding cassette transporter G member 5; *Cpt1a*, carnitine palmitoyl transferase 1 $\alpha$ ; *Cyp7a1*, cholesterol 7 $\alpha$ -hydroxylase; *Cyp8b1*, sterol 12 $\alpha$ -hydroxylase; *Cyp27a1*, sterol 27-hydroxylase; *Pgc1a*, peroxisome proliferator-activated receptor gamma coactivator 1 $\alpha$ ; *Ppara*, peroxisome proliferator-activated receptor  $\alpha$ .

expression of cholesterol 7 $\alpha$ -hydroxylase (*Cyp7a1*; +94% and +109%), a key gene involved in the classic bile acid synthesis pathway (Fig. 5D), and restored the expression of sterol 27-hydroxylase (+38%), involved in the alternative bile acid pathway (Fig. 5D). Considering that bile acid synthesis is a major pathway for hepatic cholesterol disposal [35], FGF21 likely regulates bile acid metabolism to prevent HFCD-induced cholesterol accumulation in the liver. Collectively, our data indicate that FGF21 increases the hepatic expression of key genes involved in  $\beta$ -oxidation and cholesterol removal, which together with reduced lipid overload from WAT may explain FGF21-induced alleviation of liver lipotoxicity under NASH-inducing dietary conditions.

### FGF21 prevents activation of various KC subsets

Then, we performed an in-depth phenotyping of hepatic immune cells using spectral flow cytometry. For this, we developed a panel that identifies most major immune cell subsets (for gating strategy see Fig. 6-fig. supplement 1A). As compared to LFCD, HFCD tended to reduce total CD45<sup>+</sup> leukocytes, which were increased by FGF21 (Fig. 6-fig. supplement 1B). Combining conventional gating and dimension-reduction analysis through uniform manifold approximation and projection allowed to identify FGF21-induced changes in cell subset abundance (Fig. 6A). FGF21 prevented HFCD-induced loss of eosinophils, neutrophils and B cells, and increased numbers of dendritic cells and T cells compared with those observed in both LFCD- and HFCD-fed mice (Fig. 6-fig. supplement 1B). More importantly, FGF21 increased the


number of total KCs compared with that of both LFCD- and HFCD-fed mice (+63% and +156; **Fig. 6-fig. supplement 1B**), attenuated HFCD-induced monocyte recruitment (-18%), and tended to repress the HFCD-induced increase in hepatic MoDMacs (-42%; **Fig. 6-fig. supplement 1B**).

During the development of NASH, MoDMacs can gradually seed in KC pool by acquiring ResKCs identity and replacing the dying ResKCs [36]. These recruited MoKCs can have both detrimental and supportive roles, contributing to increase in pathology during fibrosis onset, but hastening recovery when the damage-evoking agent is attenuated/removed [37]. In light of this, we assessed the abundance and phenotype of ResKCs and monocyte-derived KCs (MoKCs). We observed that FGF21 completely abolished the HFCD-induced reduction of the number of ResKCs (+319%) and potently protected against HFCD-induced ResKC activation as shown by decreased proportion of CD11c<sup>+</sup> ResKCs (-53%; **Fig. 6B**). FGF21 also completely abolished the HFCD-induced upregulation of CD36 in ResKCs, to levels that are even lower than those in LFCD-fed mice (-88% vs. LFCD; -94% vs. HFCD; **Fig. 6B**). In addition, FGF21 increased the number of MoKCs compared with that of both LFCD- and HFCD-fed mice (+92% and +123%), and prevented the HFCD-induced increase in the abundance of CD11c<sup>+</sup> MoKCs (-42%) (**Fig. 6C**). Strikingly, compared to both LFCD- and HFCD-fed mice, FGF21 downregulated CD9 (-32% and -49%) and CD36 (-98% and -100%) in MoKCs (**Fig. 6C**). Furthermore, FGF21 profoundly repressed HFCD-induced upregulation of hepatic *Tnfa* (-37%), *Il1b* (-41%) and *Ccl2* (-54%) expression to levels comparable to those in LFCD-fed mice (**Fig. 6D**), which is in line with the observation that FGF21 prevents KC activation. Given that CD36<sup>hi</sup> ResKCs and CD36<sup>hi</sup>/CD9<sup>hi</sup> MoKCs are involved in the formation of hepatic CLSs[10, 37-39], we next assessed CLSs and observed that FGF21 completely prevented the HFCD-induced formation of CLSs in the liver (-93%; **Fig. 6D**). These data demonstrate that FGF21 inhibits the activation of ResKCs and MoKCs and prevents the accumulation of CD36<sup>hi</sup> ResKCs and CD36<sup>hi</sup>/CD9<sup>hi</sup> MoKCs under dietary conditions that result in NASH, which likely contribute to the beneficial effects of FGF21 on hepatic inflammation and fibrosis.

### **FGF21 protects against COL1A1 accumulation, as predicted by the reduction of CD36<sup>hi</sup> KCs and CD9<sup>hi</sup> KCs**

To further evaluate whether FGF21-induced reductions of lipid-associated macrophages (i.e., CD36<sup>hi</sup> ResKCs and CD36<sup>hi</sup> MoKCs) [38] and scar-associated macrophages (i.e., CD9<sup>hi</sup> MoKCs) [40], are implicated in fibrogenesis, we performed multiple univariate regression analyses. These revealed that both NAFLD activity and liver fibrosis were associated with both CD36<sup>hi</sup> ResKCs, CD36<sup>hi</sup> MoKCs and CD9<sup>hi</sup> MoKCs (**Fig. 6-fig. supplement 2A-D**), indicating that FGF21 likely improves liver fibrosis by reducing these lipid-

and scar-associated macrophages. To further understand the underlying mechanisms by which FGF21 prevents liver fibrosis, we measured hepatic expression of key genes involved in fibrogenesis (**Fig. 6D**). FGF21 tended to decrease the expression of connective tissue growth factor (*Ctgf*; -27%), a major fibrogenic factor, and normalized the HFCD-induced increased expression of its downstream target collagen type I $\alpha$  1 (*Col1a1*; -61%; **Fig. 6D**). This finding was confirmed by immunohistochemistry, revealing that FGF21 reduced hepatic COL1A1 accumulation (-46%; **Fig. 6D**). Furthermore, univariate regression analysis revealed that COL1A1 expression is predicted by CD36<sup>hi</sup> ResKCs, CD36<sup>hi</sup> MoKCs and CD9<sup>hi</sup> MoKCs (**Fig. 6E, Fig. 6-fig. supplement 2E**). Taken together, these data indicate that FGF21 reduces lipid- and scar-associated macrophages to inhibit COL1A1 synthesis and prevent fibrogenesis.



## DISCUSSION

Several FGF21 analogues are currently being evaluated in clinical trials for the treatment of NASH [20, 21]. While the protective effect of pharmacological intervention with long-acting FGF21 on human liver steatosis has been uncovered [20, 21, 41], mechanisms underlying attenuated steatosis as well as all the anti-inflammatory and anti-fibrotic effects of FGF21 on NASH are still largely unexplored. Therefore, we set out to elucidate mechanisms by which FGF21 beneficially modulates these various aspects of NASH in HFD-fed *APOE\*3-Leiden.CETP* mice, a well-established model for diet-induced NASH [23, 24]. Based on our findings, we propose that FGF21 attenuates liver lipotoxicity via endocrine signaling to adipose tissue to induce thermogenesis, thereby preventing adipose tissue dysfunction to reduce lipid overflow to the liver, as well as autocrine signaling to the liver to increase FA oxidation and cholesterol removal. In addition, FGF21 prevents KC activation, monocyte recruitment and the formation of lipid- and scar-associated macrophages, thereby likely inhibiting collagen accumulation and alleviating liver fibrogenesis.

Hepatic lipotoxicity is one of the major risk factors determining the progression of liver steatosis into NASH, as shown in multiple clinical studies with obese patients [42-44]. By feeding *APOE\*3-Leiden.CETP* mice a diet rich in fat and cholesterol, we mimicked a situation in which a positive energy balance induces many aspects of the metabolic syndrome, including insulin resistance, obesity with increased fat accumulation, and hepatic lipotoxicity indicated by hepatomegaly with aberrant accumulation of TG as well as TC. Hepatic lipotoxicity likely results from lipid overflow from insulin-resistant adipose tissue towards the liver in combination with hepatic insulin resistance that prevents insulin-stimulated outflow of lipids [45]. Within this dietary context, we applied a single administration of an AAV8 vector encoding codon-optimized FGF21, which resulted in liver-specific FGF21 overexpression. Since the codon-optimized FGF21 mitigates the poor pharmacokinetic properties of native FGF21, including its short plasma half-life (0.5-2 hours) by reducing proteolytic degradation [45], an elevated level of circulating FGF21 was reached throughout the dietary intervention period. By this strategy, we mimicked the situation in which circulating FGF21 predominantly derives from the liver [46]. Indeed, circulating FGF21 correlates well with the hepatic expression of FGF21 [47]. Interestingly, hepatic expression of FGF21 fully prevented the diet-induced increase in liver weight, liver lipids (i.e., TG and TC) and steatosis score.

These lipotoxicity-protective effects of FGF21 can partially be explained by endocrine effects of liver-derived FGF21 on adipose tissue, which besides the liver has high expression of  $\beta$ -Klotho, the co-receptor of the FGFR [14, 15]. Indeed, FGF21 fully

prevented the HFD-induced increase in weights of WAT and BAT, with decreased lipid accumulation in these adipose tissue depots as well as induction of BAT activation and WAT browning. These data imply that FGF21 induces thermogenesis which increases energy expenditure, consistent with the thermogenic responses observed for recombinant FGF21 in C57BL/6 mice fed with an obesogenic diet [29]. Likewise, by using *APOE\*3-Leiden.CETP* mice, we previously reported that FGF21 treatment highly increased energy expenditure without affecting food intake [30]. Activation of thermogenic tissues by classical  $\beta$ -adrenergic receptor largely increases the uptake of circulating lipoprotein-derived FAs by BAT and beige WAT [48], which we recently also demonstrated for recombinant FGF21 [30]. This can thus at least partly explain the marked TG-lowering effect of FGF21 observed in the current study. Thermogenic activation also increases the uptake and combustion of glucose, although the glucose-lowering and insulin-sensitizing effects of FGF21 can also be explained by attenuated WAT inflammation in combination with increased adiponectin expression as well as improved liver insulin sensitivity [30, 33, 49].

Besides endocrine FGF21 signaling in adipose tissue, liver lipotoxicity is likely further prevented by autocrine FGF21 signaling. Indeed, we showed that liver-specific FGF21 overexpression increased hepatic expression of genes involved in FA oxidation (*Cpt1a*, *Ppara*, *Pgc1a*), biliary cholesterol secretion (*Abcg5*), bile acids synthesis (*Cyp7a1*) and VLDL production (*ApoB*). Of note, these observations are in line with previous reports showing increased FA oxidation [50] and upregulated *Abcg5* [51], *Cyp7a1* [51, 52] and *ApoB* [30] in the liver upon FGF21 treatment. Altogether, the marked protective effects of FGF21 on HFD-induced hepatic lipotoxicity likely results from combined endocrine and autocrine signaling, leading to reduced lipid influx from adipose tissue to the liver coupled to the activation of hepatic FA oxidation and cholesterol elimination pathways. Our observations may likely explain the recent clinical findings that treatment with FGF21 analogues in patients with NASH not only reduced hepatic steatosis [20, 21] but also increased hepatic bile acid synthesis and further promoted cholesterol removal, lowering the risk for further hepatic lipotoxicity [53].

While NASH is initiated by hepatic lipotoxicity, NASH progression is mainly driven by impaired KC homeostasis and subsequent liver inflammation [54]. Therefore, we investigated in depth the inflammatory response in the liver through a combination of immunohistochemistry, flow cytometry and gene expression analyses. HFD feeding induced an array of inflammatory effects, including increased lobular inflammation, hepatocyte ballooning and NAFLD activity scores as well as increased inflammatory foci and CLSs, accompanied by a reduction in ResKCs with a relative increase in CD11c<sup>+</sup> ResKCs, and an increase in MoDMacs and CD11c<sup>+</sup> MoKCs. These observations



are likely explained by lipotoxicity-related damage to ResKCs, and release of TNF $\alpha$ , IL-1 $\beta$  and MCP-1 (*Ccl2*), both activating various downstream pro-inflammatory mediators as well as promoting monocyte recruitment to remodel the KC pool [36, 55] and further exacerbating hepatic inflammation [10, 38, 54, 56, 57]. Importantly, FGF21 prevented most of these HFCD-induced inflammatory responses, as it normalized lobular inflammation, hepatocyte ballooning and NAFLD activity scores and CLSs, and reduced pro-inflammatory activation of various KC subsets.

Fibrosis has been identified as the most important predictor of prognosis in NAFLD patients, and therefore a main target in experimental pharmacological approaches [58]. HFCD feeding during 23 weeks induced early signs of fibrosis, as evident from an increased *Col1a1* expression and COL1A1 content, accompanied by an increased content of the hydroxyproline. Importantly, FGF21 blocked liver fibrogenesis, and decreased the hydroxyproline content. These alterations were accompanied with reductions in lipid-associated macrophages (i.e., CD36<sup>hi</sup> ResKCs/MoKCs) [38] and scar-associated macrophages (i.e., CD9<sup>hi</sup> MoKCs) [40]. In fact, when analysing the mouse groups together, CD36<sup>hi</sup> ResKCs/MoKCs and CD9<sup>hi</sup> MoKCs positively correlated with liver fibrosis as reflected by hydroxyproline content and COL1A-positive area, suggesting that these lipid- and scar-associated macrophages are involved in fibrogenesis in our model. Indeed, high numbers of CD9<sup>hi</sup> macrophages have been found in fibrotic regions of the liver [37, 39, 40, 55], and these cells are able to prime quiescent primary murine hepatic stellate cells to upregulate the expression of fibrillar collagen through CTGF [40], thereby promoting and exacerbating liver fibrosis. Therefore, we speculate that FGF21 protects against early liver fibrosis likely through preventing the accumulation of CD36<sup>hi</sup>/CD9<sup>hi</sup> KCs, thereby inhibiting activation of hepatic stellate cells to produce collagen.

This study is not without limitations. In this work, we used a gene therapy approach to examine the effects of liver-derived FGF21 on NASH based on the use of a single injection of an AAV8 vector encoding codon-optimized murine FGF21. Although AAV8 is hepatocyte trophic, we have not excluded potential contribution of other hepatic cells to total FGF21 expression. Also, while AAV8-*Fgf21* was non-toxic, sustained supra-pharmacological plasma levels of FGF21 were achieved, which do not necessarily reflect effects of current pharmacological strategies with long-acting FGF21. Interestingly, AAV-mediated gene therapy has already been tested in the clinic for life-threatening diseases such as hemophilia B, and has demonstrated stable expression of factor IX following AAV-mediated delivery [59]. Therefore, it is reasonable to speculate that liver-targeted gene therapy as an approach to induce stable overexpression of FGF21 may ultimately have potential to reach to the clinic.

In conclusion, hepatic overexpression of FGF21 in *APOE\*3-Leiden.CETP* mice limits diet-induced hepatic lipotoxicity, inflammation and fibrogenesis. Through a combination of endocrine and autocrine signaling, FGF21 reduces hepatic lipid influx and accumulation, respectively. This results in reduced macrophage activation and monocyte recruitment with less presence of lipid- and scar-associated macrophages, limiting activation of hepatic stellate cells to produce collagen (for graphic summary see **Figure 6F**). As such, our studies provide a mechanistic explanation for the hepatoprotective effects of FGF21 analogues in recent clinical trials including reduction in steatosis [20, 21, 53] as well as the fibrotic marker N-terminal type III collagen pro-peptide [20, 21], and further highlight the potential of FGF21 for clinical implementation as a therapeutic in the treatment of advanced NASH.

## MATERIALS AND METHODS

Please see the **Supplemental Materials** for a detailed description of all experimental procedures.

### Animals and treatments

Male *APOE\*3-Leiden.CETP* mice (on a C57BL/6J background) were generated as previously described [60]. Mice at the age of 10-12 weeks were group-housed (2-4 mice per cage) under standard conditions (22°C, 12/12-hour light/dark cycle) with *ad libitum* access to water and a LFCD (Standard Rodent Diet 801203, Special Diets Services, United Kingdom), unless indicated otherwise. Then, based on body weight and 4-hour (9.00-13.00) fasted plasma glucose, TG and TC levels, these mice were randomized into three treatment groups (n=18 per group), after which they received either AAV8-*Fgf21*, a liver-tropic AAV8 capsid vector expressing codon-optimized murine *Fgf21* under the control of a liver specific apolipoprotein E (*ApoE*)/alpha-1-antitrypsin (*Aat*) promoter (HFCD+FGF21 group;  $2 \times 10^{10}$  genome copies per mouse), or with the same genome copy number of AAV8-null (HFCD and LFCD groups) via a single intravenous injection. After one week of recovery, mice in the HFCD+FGF21 and HFCD groups were switched to a HFCD (60% fat and 1% cholesterol; C1090-60, Altromin, Germany) and maintained on the diet for 23 weeks, at which *APOE\*3-Leiden.CETP* mice have developed both steatosis, hepatic inflammation and early fibrosis [23, 61]. An intraperitoneal glucose tolerance test (n=8 per group) and an oral lipid tolerance test (n=10 per group) were performed at week 16 and week 20, respectively. Flow cytometry (n=5 per group) was conducted at week 23.

## **Statistics**

Comparisons among three groups were analyzed using one-way ANOVA followed by a Tukey post-test, unless indicated otherwise. Data are presented as mean $\pm$ SEM, and a *P* value of less than 0.05 was considered statistically significant. All statistical analyses were performed with GraphPad Prism 9.01 for Windows (GraphPad Software Inc., California, CA, USA).

## **Study approval**

All animal experiments were carried out according to the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals, and were approved by the National Committee for Animal Experiments (Protocol No. AVD1160020173305) and by the Ethics Committee on Animal Care and Experimentation of the Leiden University Medical Center (Protocol No. PE.18.034.041).

## **Acknowledgments**

The authors also thank T.C.M. Streefland, A.C.M. Pronk, R.A. Lalai and H.C.M. Sips from Department of Medicine, the Division of Endocrinology, Leiden University Medical Center for technical assistance.

## **Author contributions**

CL designed the study, carried out the research, analyzed and interpreted the results, and wrote and revised the manuscript. MS interpreted the results, reviewed and revised the manuscript and obtained the funding. BS and EZ carried out the research and reviewed the manuscript. JML, HJPZ and BG designed and advised the study, interpreted the results and reviewed the manuscript. MET advised the study and reviewed the manuscript. ACA, SO and KW advised the study, interpreted the results and reviewed the manuscript. AP designed AAV8-FGF21 vectors and edited the manuscript. MU and IA analyzed and interpreted the results and reviewed the manuscript. YI and X-RP provided AAV8-FGF21 vectors, advised the study, interpreted the results and reviewed the manuscript. MRB advised the study and reviewed the manuscript. YW designed and advised the study, interpreted the results, reviewed and revised the manuscript. PCNR designed and advised the study, interpreted the results, edited, reviewed and revised the manuscript and obtained the funding.

## REFERENCES

1. Cusi, K., *Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications*. *Gastroenterology*, 2012. **142**(4): p. 711-725 e6.
2. Friedman, S.L., et al., *Mechanisms of NAFLD development and therapeutic strategies*. *Nat Med*, 2018. **24**(7): p. 908-922.
3. Arab, J.P., M. Arrese, and M. Trauner, *Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease*. *Annual Review of Pathology: Mechanisms of Disease*, Vol 13, 2018. **13**: p. 321-350.
4. Taylor, R.S., et al., *Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta -Analysis*. *Gastroenterology*, 2020. **158**(6): p. 1611-+.
5. Stefan, N., H.U. Haring, and K. Cusi, *Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies*. *Lancet Diabetes Endocrinol*, 2019. **7**(4): p. 313-324.
6. Musso, G., R. Gambino, and M. Cassader, *Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)*. *Progress in Lipid Research*, 2009. **48**(1): p. 1-26.
7. Neuschwander-Tetri, B.A., *Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites*. *Hepatology*, 2010. **52**(2): p. 774-88.
8. Tacke, F., *Targeting hepatic macrophages to treat liver diseases*. *J Hepatol*, 2017. **66**(6): p. 1300-1312.
9. Krenkel, O. and F. Tacke, *Liver macrophages in tissue homeostasis and disease*. *Nat Rev Immunol*, 2017. **17**(5): p. 306-321.
10. Tran, S., et al., *Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-alcoholic Steatohepatitis*. *Immunity*, 2020. **53**(3): p. 627-640 e5.
11. Krenkel, O., et al., *Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis*. *Hepatology*, 2018. **67**(4): p. 1270-1283.
12. Meng, W., et al., *The miR-182-5p/FGF21/acetylcholine axis mediates the crosstalk between adipocytes and macrophages to promote beige fat thermogenesis*. *Jci Insight*, 2021. **6**(17).
13. Guo, Y., et al., *Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions*. *Lipids Health Dis*, 2016. **15**(1): p. 208.
14. Fisher, F.M. and E. Maratos-Flier, *Understanding the Physiology of FGF21*. *Annu Rev Physiol*, 2016. **78**: p. 223-41.
15. Geng, L., K.S.L. Lam, and A. Xu, *The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic*. *Nat Rev Endocrinol*, 2020. **16**(11): p. 654-667.
16. Zhang, X., et al., *Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans*. *Diabetes*, 2008. **57**(5): p. 1246-53.
17. Barb, D., et al., *Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes*. *J Clin Endocrinol Metab*, 2019. **104**(8): p. 3327-3336.
18. Li, H., et al., *Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride*. *J Hepatol*, 2010. **53**(5): p. 934-40.
19. Flippo, K.H. and M.J. Potthoff, *Metabolic Messengers: FGF21*. *Nat Metab*, 2021. **3**(3): p. 309-317.
20. Sanyal, A., et al., *Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial*. *Lancet*, 2019. **392**(10165): p. 2705-2717.

21. Harrison, S.A., et al., *Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial*. Nat Med, 2021. **27**(7): p. 1262-1271.
22. Bao, L.C., et al., *A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway*. British Journal of Pharmacology, 2018. **175**(16): p. 3379-3393.
23. Morrison, M.C., et al., *Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE( <sup>\*</sup>)3Leiden mice*. J Hepatol, 2015. **62**(5): p. 1180-6.
24. Liang, W., et al., *Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology*. PLoS One, 2014. **9**(12): p. e115922.
25. van den Hoek, A.M., *APOE\*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome*. Diabetes, 2013. **16**: p. 537-544.
26. van der Hoorn, J.W., et al., *The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE\*3Leiden.CETP transgenic mice*. Br J Pharmacol, 2009. **156**(7): p. 1067-75.
27. Li, Z., et al., *Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit*. Gut, 2018. **67**(7): p. 1269-1279.
28. Duivenvoorden, I., et al., *Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE\*3Leiden mice*. Am J Clin Nutr, 2006. **84**(2): p. 312-21.
29. Schlein, C., et al., *FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues*. Cell Metab, 2016. **23**(3): p. 441-53.
30. Liu, C., et al., *Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis*. Cardiovasc Res, 2021.
31. Zhang, F., et al., *An Adipose Tissue Atlas: An Image-Guided Identification of Human-like BAT and Beige Depots in Rodents*. Cell Metab, 2018. **27**(1): p. 252-262 e3.
32. Mulder, P., et al., *Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity*. Int J Obes (Lond), 2016. **40**(4): p. 675-84.
33. Lin, Z., et al., *Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice*. Cell Metab, 2013. **17**(5): p. 779-89.
34. Machado, M.V. and A.M. Diehl, *Pathogenesis of Nonalcoholic Steatohepatitis*. Gastroenterology, 2016. **150**(8): p. 1769-77.
35. Tu, H., *FXR, a Bile Acid Receptor and Biological Sensor*. Trends in Cardiovascular Medicine, 2000. **10**(1): p. 30-35.
36. Tran, S., et al., *Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-alcoholic Steatohepatitis*. Immunity, 2020. **53**(3): p. 627-+.
37. Seidman, J.S., et al., *Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis*. Immunity, 2020. **52**(6): p. 1057-1074 e7.
38. Blieriot, C., et al., *A subset of Kupffer cells regulates metabolism through the expression of CD36*. Immunity, 2021. **54**(9): p. 2101-+.
39. Daemen, S., et al., *Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH*. Cell Rep, 2021. **34**(2): p. 108626.
40. Ramachandran, P., et al., *Resolving the fibrotic niche of human liver cirrhosis at single-cell level*. Nature, 2019. **575**(7783): p. 512-+.

41. Aggarwal, P., et al., *Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials*. Expert Opinion on Investigational Drugs, 2022.
42. Bril, F., et al., *Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease*. Hepatology, 2017. **65**(4): p. 1132-1144.
43. Armstrong, M.J., et al., *Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis*. J Hepatol, 2016. **64**(2): p. 399-408.
44. Ratziu, V., et al., *Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial*. Nat Med, 2021. **27**(10): p. 1825-1835.
45. Zarei, M., et al., *Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis*. Trends Pharmacol Sci, 2020. **41**(3): p. 199-208.
46. Nishimura, T., et al., *Identification of a novel FGF, FGF-21, preferentially expressed in the liver*. Biochim Biophys Acta, 2000. **1492**(1): p. 203-6.
47. Markan, K.R., et al., *Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding*. Diabetes, 2014. **63**(12): p. 4057-4063.
48. Berbee, J.F., et al., *Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development*. Nat Commun, 2015. **6**: p. 6356.
49. Yang, Q., A. Vijayakumar, and B.B. Kahn, *Metabolites as regulators of insulin sensitivity and metabolism*. Nat Rev Mol Cell Biol, 2018. **19**(10): p. 654-672.
50. Fisher, F.M., et al., *Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets*. Gastroenterology, 2014. **147**(5): p. 1073-83 e6.
51. Keinicke, H., et al., *FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation*. Endocr Connect, 2020. **9**(8): p. 755-768.
52. Zhang, J., et al., *Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action*. EBioMedicine, 2017. **15**: p. 173-183.
53. Luo, Y., et al., *Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis*. JHEP Rep, 2022. **4**(1): p. 100392.
54. Cai, J., X.J. Zhang, and H. Li, *The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis*. Hepatology, 2019. **70**(3): p. 1026-1037.
55. Remmerie, A., et al., *Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver*. Immunity, 2020. **53**(3): p. 641-+.
56. Schwabe, R.F., I. Tabas, and U.B. Pajvani, *Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis*. Gastroenterology, 2020. **158**(7): p. 1913-1928.
57. Yu, Y., et al., *STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis*. J Clin Invest, 2019. **129**(2): p. 546-555.
58. Heyens, L.J.M., et al., *Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment*. Frontiers in Medicine, 2021. **8**.
59. Nathwani, A.C., et al., *Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer*. Blood, 2018. **132**.

60. Westerterp, M., et al., *Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE\*3-Leiden mice*. *Arterioscler Thromb Vasc Biol*, 2006. **26**(11): p. 2552-9.
61. Hui, S.T., et al., *The Genetic Architecture of Diet-Induced Hepatic Fibrosis in Mice*. *Hepatology*, 2018. **68**(6): p. 2182-2196.

## SUPPLEMENT

### Expanded methods

#### *Generation of recombinant adeno-associated virus (AAV) vectors*

AD-293 cells (Agilent, Santa Clara, CA, USA) were plated in a five layered chamber in Gibco™ DMEM supplemented with 10% Gibco™ FBS and 1% Gibco™ penicillin-streptomycin (Thermo Fisher Scientific, Waltham, MA, USA). When these cells reached at 60-85% confluency under the microscope, they were transfected by polyethylenimine (Polyscience, Torrance, CA, USA) with triple plasmids, including pHelper containing adenoviral E2A and E4 genes, pRep2Cap8 encoding AAV2 Rep proteins and AAV8 serotype capsid, and either pAAV-apolipoprotein E (*ApoE*)/alpha-1-antitrypsin (*Aat*) promoter-driven codon-optimized murine *Fgf21* or pAAV-*ApoE*/no plasmid, in a ratio of 2:1.4:1, respectively. After 72 hours of the post-transfection, cells were harvested and lysed via three freeze-thaw cycles followed by 1 hour of benzonase treatment at 37°C. Supernatants were then further purified using iodixanol gradient based ultracentrifugation. Titers of all AAV vectors used for *in vivo* study were quantitated by quantitative reverse transcriptase-PCR. Given that the AAV8 vector is naturally mouse hepatocyte trophic, the AAT promoter is highly active in hepatocytes, and hepatocytes have a slow turnover, this approach results in sustained hepatocyte-selective expression of murine *Fgf21* in the long-term. Since the recombinant AAV8 vector was generated by a standard and helper-free 3 plasmid transfection system, this vector does not express AAV8 and adenoviral helper proteins, and cannot replicate in transduced hepatocytes. Pilot data in C57BL/6 mice showed that the AAV8-*Fgf21* vector ( $3 \times 10^{10}$ ,  $1 \times 10^{11}$  and  $1 \times 10^{12}$  genome copies/mouse) did not cause liver injury, as judged from unaffected alanine transaminase (ALT) and aspartate transaminase (AST) levels in plasma at 8 days after injection.

#### *Body weight and plasma glucose, triglycerides (TG) and total cholesterol (TC)*

Body weight (n=18 per group) was recorded weekly of all mice throughout the study. Every 4 weeks, mice were fasted for 4 hours (9.00-13.00), and subsequently, tail vein blood was collected into paraoxon-coated glass capillaries. Plasma (n=18 per group) was collected and measured for glucose, TG and TC using commercial enzymatic kits (Roche Diagnostics, Mannheim, Germany).

#### *Plasma FGF21, adiponectin and lipoprotein profile*

Plasma FGF21 concentrations were determined at week -1 (pooled samples, n=6 per group), week 4 (pooled samples, n=6 per group) and week 23 (n=12-16 per group) using Mouse/Rat FGF21 Quantikine ELISA Kit (R&D Systems, Minneapolis, NE, USA).



Plasma adiponectin levels were measured at week 22 (n=10 per group) using Mouse Adiponectin/Acrp30 Quantikine ELISA Kit (R&D Systems, Minneapolis, NE, USA). At week 22, 4  $\mu$ L of 4-hour fasting plasma per mouse (n=18 per group) were pooled in each treatment group to measure the distribution of TG and TC over lipoproteins by fast-performance liquid chromatography using Super 6 column (GE Healthcare, Piscataway, NJ, USA).

#### *Glucose tolerance test and lipid tolerance test*

At week 16, an intraperitoneal glucose tolerance test (IPGTT) was performed with an injection of D-glucose (2 g/kg body weight) after 4 hours fasting (9.00-13.00; n=8 per group). Blood was collected via tail vein at 0, 5, 15, 30, 60 and 120 min for each test. The glucose was measured with a OneTouch Ultra glucometer (AccuCheck Sensor, Roche Diagnostics, Almere, The Netherlands), and the area under the curve (AUC) was calculated. During IPGTT, extra blood was collected at 0 and 15 min, spun down, and the serum samples were stored at -20°C for glucose measurement using a commercial enzymatic kit (Roche Diagnostics; Mannheim, Germany) and insulin measurement using an Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem, Zaandam, The Netherlands). HOMA-IR was calculated with the following formula: [fasting serum glucose (mM)  $\times$  fasting serum insulin ( $\mu$ U/mL)]/22.5 [1]. At week 20, oral lipid tolerance test was conducted. To this end, mice (n=10 per group) were fasted for 4 hours (9.00-13.00h), and received olive oil (10 mL/kg body weight) via oral gavage. Blood was collected into paraoxon-coated glass capillaries at 0, 2, 4, 6 and 8 hours, spun down, and the plasma samples were stored at -20°C for TG measurement using commercial enzymatic kits (Roche Diagnostics, Mannheim, Germany).

#### *Hepatic lipids and hydroxyproline*

Hepatic lipids were extracted from snap-frozen liver samples (n=18 per group) using a modified protocol from Bligh and Dyer [2]. Liver TG, TC and phospholipid (PL; Instruchemie, Delfzijl, The Netherlands) and protein (Pierce, Thermo Fisher Scientific, Waltham, MA, USA) concentrations were measured. Hepatic lipids were expressed as nmol per mg protein. Hepatic hydroxyproline concentrations (n=18 per group) were determined using a Mouse Hydroxyproline Assay Kit (QuickZyme Biosciences, Leiden, The Netherlands).

#### *Adipose tissue Histology*

Formalin-fixed paraffin-embedded interscapular brown adipose tissue (iBAT), subcutaneous white adipose tissue (sWAT) and gonadal white adipose tissue (gWAT) sections (5  $\mu$ m thickness) were prepared for hematoxylin-eosin (H&E) staining[3]. Moreover, iBAT and sWAT sections were processed for uncoupling protein-1 (UCP-1)

staining [4], and gWAT sections were used for F4/80 staining [5]. The areas occupied by intracellular lipid vacuoles (n=18 per group) and UCP-1 (n=18 per group) were quantified using Image J software (version 1.52a; National Institutes of Health, Bethesda, Maryland). Using Image J software, the size of adipocyte of gWAT (n=18 per group) and sWAT (n=18 per group) and the number of crown-like structures (CLSs) within the gWAT (n=18 per group) were assessed. The number of CLSs in the gWAT was expressed as the number of CLS per mm<sup>2</sup>.

#### *Liver histology and histological grading of NAFLD activity score*

Liver tissue (n=18 per group) was fixed, embedded and sectioned (5 µm thickness) for H&E, oil red O (ORO), F4/80, Picosirius Red (PSR) and COL1A1 staining. The number of CLS in the liver was counted using Image J software and expressed as the number of CLS per mm<sup>2</sup>. In addition, hepatic collagen accumulation was evaluated by quantifying Picosirius Red- and COL1A1-positive areas in the liver using Image J software. For NAFLD activity score determination, a clinically utilized scoring system was adapted for the current study based on liver section H&E staining [6]. The scoring system is ranged from 0-7, and is evaluated semi-quantitatively through three criterions: steatosis (0-3), lobular inflammation (0-2), and hepatocellular ballooning (0-2). Values in figures for each staining present means of 6-9 different and randomly analyzed fields (~1.5 mm<sup>2</sup>) of each mouse, and were used for statistical analysis.

#### *Gene expression analysis*

Total RNA was isolated from snap-frozen tissues (n=18 per group for each tissue) using TriPure RNA Isolation Reagent (Roche Diagnostics, Mijdrecht, The Netherlands). Thereafter, complementary DNA for quantitative reverse transcriptase-PCR was generated using Moloney Murine Leukemia Virus Reverse Transcriptase (Promega, Leiden, the Netherlands). Then, mRNA expression was normalized to *Actb* and *Rplp0* mRNA levels and expressed as fold change compared with the LFC group. The primer sequences are listed in the **Appendix-table 1**.

#### *Isolation of hepatic leukocytes*

At the end of the study, livers (n=5 per group) were collected in ice-cold RPMI 1640+Glutamax (Thermo Fisher Scientific, Waltham, MA, USA). The tissues were subsequently minced and digested for 45 min at 37°C in RPMI 1640+Glutamax supplemented with 1 mg/mL collagenase type IV from *Clostridium histolyticum* (Sigma-Aldrich, St. Louis, MO, USA), 2000 U/mL DNase (Sigma-Aldrich, St. Louis, MO, USA) and 1 mM CaCl<sub>2</sub> as previously described [7]. The digested liver tissues were passed through a 100 µm cell strainer and washed with PBS supplemented with 0.5% BSA and 2 mM EDTA (PBS/BSA/EDTA). The samples were spun down (530 x g, 10 min at 4°C) after

which the pellet was resuspended in PBS/BSA/EDTA and centrifuged at 50 x g to pellet the hepatocytes (3 min at 4°C). The supernatant was next collected and centrifuged (530 x g, 10 min at 4°C) after which the pellet was treated with erythrocyte lysis buffer (0.15 M NH<sub>4</sub>Cl; 1 mM KHCO<sub>3</sub>; 0.1 mM Na<sub>2</sub>EDTA) for 2 min at room temperature. After washing with PBS/BSA/EDTA, total leukocytes were isolated by means of Magnetic-activated cell sorting (MACS) using LS columns and CD45 MicroBeads (35 µL beads per liver; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's protocol. Isolated CD45<sup>+</sup> cells were counted and stained with Zombie NIR (Biolegend, San Diego, CA, USA) for 20 min at room temperature followed by fixation with 1.9% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) for 15 min at room temperature after which the fixed leukocytes were further processed for flow cytometry.

#### *Flow cytometry*

For analysis of hepatic leukocyte subsets, isolated CD45<sup>+</sup> cells were incubated with a cocktail of antibodies directed against XCR1, CD11c, CD19, Ly6G, F4/80, MHC-II, CD45, CLEC2, Siglec-F, CD64, CD8, NK1.1, CD11b, CD4, CD90.2, Ly6C, CD3, CD36, CD9 and TIM4 in PBS/BSA/EDTA supplemented with True-Stain monocyte blocker (Biolegend, San Diego, CA, USA) and Brilliant Stain Buffer Plus (BD Biosciences, Franklin Lakes, NJ, USA) for 30 min at 4°C. The stained samples (n=5 per group) were measured by spectral flow cytometry using a Cytex Aurora spectral flow cytometer (Cytex Biosciences, Fremont, CA, USA). Spectral unmixing of the flow cytometry data was performed using SpectroFlo v3.0 (Cytex Biosciences, Fremont, CA, USA). Gating of flow cytometry data was performed using FlowJo™ v10.8 Software (BD Biosciences, Franklin Lakes, NJ, USA). Dimensionality reduction by means of Uniform Manifold Approximation and Projection (UMAP) was performed using OMIQ data analysis software (Omiq inc, Santa Clara, CA, USA). Statistical analysis was performed using GraphPad version 9.01 for Windows (GraphPad Software, La Jolla, CA, USA). Representative gating strategies are shown in **Fig. S5A** and information regarding the antibodies used is listed in **Appendix-table 2**.

## REFERENCES

1. Fraulob, J.C., et al., *A Mouse Model of Metabolic Syndrome: Insulin Resistance, Fatty Liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 Mice Fed a High Fat Diet*. J Clin Biochem Nutr, 2010. **46**(3): p. 212-23.
2. Bligh, E.G. and W.J. Dyer, *A rapid method of total lipid extraction and purification*. Can J Biochem Physiol, 1959. **37**(8): p. 911-7.
3. Cardiff, R.D., C.H. Miller, and R.J. Munn, *Manual hematoxylin and eosin staining of mouse tissue sections*. Cold Spring Harb Protoc, 2014. **2014**(6): p. 655-8.
4. Kooijman, S., et al., *Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice*. Diabetologia, 2015. **58**(11): p. 2637-46.
5. Lanthier, N., et al., *Kupffer cell activation is a causal factor for hepatic insulin resistance*. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2010. **298**(1): p. G107-G116.
6. Bedossa, P., et al., *Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients*. Hepatology, 2012. **56**(5): p. 1751-9.
7. van der Zande, H.J.P., et al., *The helminth glycoprotein omega-1 improves metabolic homeostasis in obese mice through type 2 immunity-independent inhibition of food intake*. Faseb Journal, 2021. **35**(2).


**Appendix-table 1. List of polymerase chain reaction primer sequences used in mRNA expression analysis.**

Gene	Forward primer (5'-3')	Reverse Primer (5'-3')
<i>Abcg5</i>	GAGCTGCAGAGGATGATTGCT	AGCCACCCTGGTCTTGGGA
<i>Acta2</i>	CCTGACGGGCAGGTGATC	ATGAAAGATGGCTGGAAGAGAGTCT
<i>Actb</i>	AACCGTGAAAAGATGACCCAGAT	CACAGCCTGGATGGCTACGTA
<i>Adgre1</i>	CTTTGGCTATGGCTTCCAGTC	GCAAGGAGGACAGAGTTTATCGTG
<i>Adipoq</i>	CTCCACCCAAGGAACTTGT	TAGGACCAAGAAGACCTGCATC
<i>Apob</i>	GCCCATGTGGACAAGTTGATC	CCAGGACTTGGAGTCTTGGGA
<i>Ccl2</i>	GCATCTGCCCTAAGGTCTTCA	TTCCTGTACACTGGTCACTCCTA
<i>Cd36</i>	GCAAAGAACAGCAGCAAAATC	CAGTGAAGGCTCAAAGATGG
<i>Col1a1</i>	GAGAGAGCATGACCGATGGATT	TGTAGGCTACGCTGTCTTGGCA
<i>Cpt1a</i>	GAGACTTCCAACGCATGACA	ATGGGTGGGGTGATGTAGA
<i>Ctgf</i>	GGCCTCTTCTGCGATTTTCG	CCATCTTTGGCAGTGCACACT
<i>Cyp7a1</i>	CAGGGAGATGCTCTGTGTTC	AGGCATACATCCCTTCCGTGA
<i>Cyp8b1</i>	GGACAGCCTATCCTTGGTGA	CGGAACCTTCCTGAACAGCTC
<i>Cyp27a1</i>	TCTGGCTACCTGCCTTCTCT	CTGGATCTCTGGGCTCTTTG
<i>Codon-optimized Fgf21</i>	GCCCACCTGGAGATCAGGGAGGA	GGCAGGAAGCGCACAGGTCCCCAG
<i>Fgf21</i>	GGGGTCATTCAAATCCTGGGTGTCA	ACACATTGTAACCGTCTCCAGCAG
<i>Fgfr1</i>	AGAGTCCAAGAGTAAAAGCAGC	CTTCCGAGGTTTCAGCTCTCC
<i>Fgfr2</i>	GCTATAAGGTACGAAACCAGCAC	GGTTGATGGACCCGATTCATTC
<i>Fgfr4</i>	TCCATGACCGTCGTACACAAT	ATTTGACAGTATTTCCGGCAG
<i>Il1b</i>	GCAACTGTCTCTGAACTCAACT	ATCTTTTGGGGTCCGTCACACT
<i>Klb</i>	TGTTCTGCTGCGAGCTGTTAC	TACCGGACTCACGTACTGTTT
<i>Mttp</i>	CTCTTGGCAGTGCTTTTTCTCT	GAGCTTGATAGCCGCTCATT
<i>Pgc1a</i>	TGCTAGCGGTTCTCACAGAG	AGTGCTAAGACCGCTGCATT
<i>Ppara</i>	ATGCCAGTACTGCCGTTTTTC	GGCCTTGACCTTGTTTCATGT
<i>Rplp0</i>	GGACCCGAGAAGACCTCCTT	GCACATCACTCAGAATTTCAATGG
<i>Tgfb1</i>	TTGCCCTCTACAACCAACACAA	GGCTTGCGACCCACGTAGTA
<i>Tnfa</i>	AGCCCACGTCGTAGCAAACCAC	TCGGGGCAGCCTTGTCCTT


*Abcg5*, ATP-binding cassette transporter G member 5; *Acta2*, actin  $\alpha$  2; *Actb*,  $\beta$ -actin *Adgre1*, adhesion G protein-coupled receptor E1; *Adipoq*, adiponectin; *Apob*, apolipoprotein B; *Ccl2*, C-C motif chemokine ligand 2; *Cd36*, cluster of differentiation 36; *Col1a1*, collagen type 1 $\alpha$ 1; *Cpt1a*, carnitine palmitoyl transferase 1 $\alpha$ ; *Ctgf*, connective tissue growth factor; *Cyp7a1*, cholesterol 7 $\alpha$ -hydroxylase; *Cyp8b1*, sterol 12 $\alpha$ -hydroxylase; *Cyp27a1*, sterol 27-hydroxylase; *Fgf21*, exogenous fibroblast growth factor; *Fgfr*, fibroblast growth factor receptor; *Il1b*, interleukin-1 $\beta$ ; *Klb*,  $\beta$ -Klotho; *Pgc1a*, peroxisome proliferator-activated receptor gamma coactivator 1 $\alpha$ ; *Ppara*, peroxisome proliferator-activated receptor  $\alpha$ ; *Rplp0*, ribosomal protein lateral stalk subunit p0; *Tgfb1*, transforming growth factor- $\beta$ ; *Tnfa*, tumor necrosis factor  $\alpha$ .

**Appendix-table 2. List of antibodies and other reagents used for flow cytometry analyses**


Target	Clone	Conjugate	Source	Catalog number
CD3	17A2	APC/Fire-810	Biolegend	100267
CD4	RM4-5	APC	eBioscience	17-0042-83
CD8	RPA-T8	PE-Cy5	BD Biosciences	561951
CD9	MZ3	PerCP-Cy5.5	Biolegend	124817
CD11b	M1/70	PE-Cy7	eBioscience	25-0112-82
CD11c	HL3	V450	BD Biosciences	560521
CD19	1D3	BV480	BD Biosciences	566107
CD36	HM36	PE	Biolegend	102606
CD45	30-F11	BV785	Biolegend	103149
CD64	X54-5/7.1	PE-DAZZLE594	Biolegend	139320
CD90.2	30-H12	Alexa Fluor 700	Biolegend	105319
CLEC2	17D9	FITC	Bio-Rad	MCA5700
F4/80	BM8	BV711	Biolegend	123147
Ly6C	HK1.4	APC-Cy7	Biolegend	128025
Ly6G	1A8	BV650	Biolegend	127641
MHC-II	M5/114.15.2	BV750	BD Biosciences	747458
MHC-II	M5/114.15.2	Alexa Fluor 700	Thermo Fisher	56-5321-82
NK1.1	PK136	PerCP-Cy5.5	Biolegend	108727
Siglec-F	E50-2440	PE	BD Biosciences	552126
Siglec-F	E50-2440	BV605	BD Biosciences	740388
TIM4	54 (RMT4-54)	PerCP-eFluor710	Thermo Fisher	46-5866-82
XCR1	ZET	BV421	Biolegend	148216
<b>Other reagents</b>				
	Zombie NIR™ Fixable Viability Kit		Biolegend	423106
	True-Stain Monocyte Blocker		Biolegend	426103
	Brilliant Stain Buffer Plus		BD Biosciences	566385




**Fig. 2-fig. supplement 1. Liver-specific FGF21 overexpression tends to upregulate mRNA expression of FGF21 receptor 1 (FGFR1) and co-receptor  $\beta$ -Klotho (KLB) in white adipose tissue (WAT).** The mRNA expression of KLB and FGFR1 in gonadal WAT (gWAT). Data are shown as mean  $\pm$  SEM (n=16-18 per group). Differences were assessed using one-way ANOVA followed by a Tukey post-test.




**Fig. 3-fig. supplement 1. HFCD increases fasting cholesterol levels.** (A) Fasting plasma total cholesterol (TC) levels were measured over a 23-week intervention period (n=14-18 per group), and (B) the distribution of the cholesterol over circulating lipoproteins was assessed at week 22 (pooled samples; n=18 per group). Data are shown as mean  $\pm$  SEM. Differences were assessed using one-way ANOVA followed by a Tukey post-test. \*\*\* $P < 0.001$ , compared with the LFCD group. VLDL, very low-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.



**Fig. 4-fig. supplement 1. FGF21 abolishes HFCD-induced increase of hepatic lipid-positive area and the number of inflammatory foci.** At week 23, (A) hepatic lipid droplet content and (B) inflammatory foci numbers were assessed by H&E staining. Data are shown as mean  $\pm$  SEM (n=18 per group). Differences were assessed using one-way ANOVA followed by a Tukey post-test. \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , compared with the LFCD group. \* $P < 0.01$  ### $P < 0.001$ , compared with the HFCD group.




**Fig. 5-fig. supplement 1. Liver-specific FGF21 overexpression upregulates hepatic mRNA expression of FGF21 receptors (FGFRs) and co-receptor  $\beta$ -Klotho (KLB).** The mRNA levels of KLB and FGFRs in the liver. Data are shown as mean $\pm$ SEM (n=14-18 per group). Differences were assessed using one-way ANOVA followed by a Tukey post-test. \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001, compared with the LFCD group. ## $P$ <0.01, ### $P$ <0.001, compared with the HFCD group.




**Fig. 5-fig. supplement 2. FGF21 increases apolipoprotein B mRNA (*Apob*) expression in the liver.** At end of the study, hepatic expression of genes involved in (A) fatty acid uptake and (B) VLDL production was quantified (n=15-18 per group). Data are shown as mean $\pm$ SEM. Differences were assessed using one-way ANOVA followed by a Tukey post-test. \*\*\* $P$ <0.001, compared with the LFCD group. ### $P$ <0.001, compared with the HFCD group. *Apob*, apolipoprotein B; *Cd36*, cluster of differentiation 36; *Mttp*, microsomal triglyceride transfer protein.





**Fig. 6-fig. supplement 1. FGF21 modulates the hepatic immune cell pool.** (A) Flow cytometry gating strategy. (B) After 23 weeks of treatment, CD45<sup>+</sup> cells were isolated from the liver, and the number of CD45<sup>+</sup> cells, eosinophils, neutrophils, B cells, dendritic cells (DCs), T cells, natural killer (NK) cells, total Kupffer cells (KCs), Ly6C<sup>hi</sup> monocytes and monocyte-derived macrophages (MoDMacs) was assessed. Data are shown as mean±SEM (n=4-5 per group). Differences were assessed using one-way ANOVA followed by a Fisher's LSD test. \* $P < 0.05$ , \*\* $P < 0.01$ , compared with the LFCD group. \* $P < 0.05$ , \*\* $P < 0.01$ , compared with the HFCD group.



**Fig. 6-fig. supplement 2. CD36<sup>hi</sup> ResKCs as well as CD36<sup>hi</sup>/CD9<sup>hi</sup> MoKCs positively correlate with NAFLD activity score and liver fibrosis.** NAFLD activity scores and liver hydroxyproline levels were plotted against the expression of (A) CD9 and (B) CD36 in ResKCs as well as (C) CD9 and (D) CD36 in MoKCs. (E) Hepatic expression of collagen type 1 $\alpha$  1 (COL1A1) was plotted against the expression of CD9 in ResKCs. Linear regression analyses were performed. Data are represented as mean  $\pm$  SEM (n=5 per group).